Drug Calculation Errors in Anesthesiology Residents and Faculty: An Analysis of Contributing Factors

Limited data exist regarding computational drug error rates in anesthesia residents and faculty. We investigated the frequency and magnitude of computational errors in a sample of anesthesia residents and faculty. With institutional review board approval from 7 academic institutions in the United States, a 15-question computational test was distributed during rounds. Error rates and the magnitude of the errors were analyzed according to resident versus faculty, years of practice (or residency training), duration of sleep, type of question, and institution. A total of 371 completed the test: 209 residents and 162 faculty. Both groups committed 2 errors (median value) per test, for a mean error rate of 17.0%. Twenty percent of residents and 25% of faculty scored 100% correct answers. The error rate for postgraduate year 2 residents was less than for postgraduate year 1 (P = .012). The error rate for faculty increased with years of experience, with a weak correlation (R = 0.22; P = .007). The error rates were independent of the number of hours of sleep. The error rate for percentage-type questions was greater than for rate, dose, and ratio questions (P = .001). The error rates varied with the number of operations needed to calculate the answer (P < .001). The frequency of large errors (100-fold greater or less than the correct answer) by residents was twice that of faculty. Error rates varied among institutions ranged from 12% to 22% (P = .021). Anesthesiology residents and faculty erred frequently on a computational test, with junior residents and faculty with more experience committing errors more frequently. Residents committed more serious errors twice as frequently as faculty

Should We Start Prescribing Omega-3 Polyunsaturated Fatty Acids in Chronic Heart Failure?

Chronic heart failure (HF) represents a significant health care burden. Over the past few decades, there have been considerable data supporting the benefits of omega-3 polyunsaturated fatty acids (PUFAs) on overall cardiovascular health. Reasons for the potential benefits of omega-3 PUFAs are multifactorial and not completely understood. It is likely that the culmination of multiple effects collectively help to prevent the development and slow the progression of chronic HF. A number of key epidemiologic and randomized trials have provided the basis of evidence in support of omega-3 PUFA supplementation in HF. This article reviews the benefits of omega-3 PUFAs and discusses the implications of recent trials. While the benefits seen in patients with chronic HF are modest at best, we believe the balance of evidence still favors the continuation of omega-3 PUFA supplementation in patients with chronic HF